Public Comments

MAPS staff members provide public comments to governmental bodies about proposed legislation or regulations concerning psychedelics during time periods prescribed by law.

  • Testimony to U.S. Sentencing Commission re: MDMA
    Written by Rick Doblin, Ph.D, in collaboration with Ismail L. Ali, JD, and Natalie Lyla Ginsberg, M.S.W. | March 15, 2017
  • The Federal Government Should Fund Clinical Research into the Uniquely Effective Treatment Ibogaine to Treat Opioid Addiction
    Public Comment Submitted to President’s Commission on Combating Drug Addiction and the Opioid Crisis | June 16, 2017